SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 60 filers reported holding SUTRO BIOPHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $15,035,000 | +6.5% | 2,708,975 | 0.0% | 0.30% | -2.0% |
Q2 2022 | $14,114,000 | -36.6% | 2,708,975 | 0.0% | 0.30% | -13.5% |
Q1 2022 | $22,268,000 | -44.8% | 2,708,975 | 0.0% | 0.35% | -32.2% |
Q4 2021 | $40,310,000 | -10.0% | 2,708,975 | +14.3% | 0.52% | -12.9% |
Q3 2021 | $44,788,000 | +1.6% | 2,370,975 | 0.0% | 0.59% | -0.2% |
Q2 2021 | $44,076,000 | -18.3% | 2,370,975 | 0.0% | 0.59% | -26.0% |
Q1 2021 | $53,963,000 | +4.8% | 2,370,975 | 0.0% | 0.80% | +1.4% |
Q4 2020 | $51,474,000 | +157.9% | 2,370,975 | +19.4% | 0.79% | +101.8% |
Q3 2020 | $19,959,000 | +29.5% | 1,985,975 | 0.0% | 0.39% | +16.7% |
Q2 2020 | $15,411,000 | +17.5% | 1,985,975 | +54.4% | 0.34% | -21.2% |
Q1 2020 | $13,117,000 | -4.2% | 1,285,975 | +3.3% | 0.42% | +10.1% |
Q4 2019 | $13,694,000 | +187.0% | 1,244,895 | +137.1% | 0.39% | +144.3% |
Q3 2019 | $4,772,000 | -65.3% | 525,000 | -57.8% | 0.16% | -62.2% |
Q2 2019 | $13,758,000 | -0.1% | 1,244,895 | 0.0% | 0.42% | -11.8% |
Q1 2019 | $13,770,000 | +26.3% | 1,244,895 | 0.0% | 0.47% | -1.9% |
Q4 2018 | $10,904,000 | -39.9% | 1,244,895 | 0.0% | 0.48% | -27.5% |
Q3 2018 | $18,134,000 | – | 1,244,895 | – | 0.67% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 1,675,579 | $5,814,259 | 1.78% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,883,693 | $20,416,415 | 1.10% |
Kynam Capital Management, LP | 1,552,675 | $5,387,782 | 0.88% |
Parkman Healthcare Partners LLC | 1,182,168 | $4,102,123 | 0.75% |
Rubric Capital Management LP | 3,344,810 | $11,606,491 | 0.44% |
BVF INC/IL | 3,347,946 | $11,617,373 | 0.31% |
DAFNA Capital Management LLC | 283,079 | $982,284 | 0.31% |
SECTORAL ASSET MANAGEMENT INC | 432,339 | $1,500,216 | 0.29% |
Eversept Partners, LP | 769,638 | $2,670,644 | 0.23% |
Frazier Life Sciences Management, L.P. | 780,000 | $2,706,600 | 0.18% |